Identifying life-threatening VITT using a highly specific ELISA

Vaccine-induced immune thrombocytopenia and thrombosis has been identified as a rare side effect of the ChAdOx1 nCoV-19 adenoviral vector vaccine. Alex Stephenson-Brown explains how an ELISA from Stago can detect cases of the condition.

As vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new condition, there is limited evidence available to inform clinical management. Recent research1 by the UK’s Expert Haematology Panel indicates overall mortality to be as high as 22%, with the greatest risk of death from those presenting with both a low platelet count and an intracranial haemorrhage. Most were previously fit and healthy young people. The National Institute for Health and Care Excellence (NICE) has also adapted its own recent guidelines based on this haematology panel’s findings.2 Fortunately, treatment options are available, with early interventions thought to produce the best outcomes.

            Vaccine-induced immune thrombocytopenia and thrombosis is primarily caused by the patient’s blood developing an antibody that cross reacts with platelet factor 4 and activates the platelets. However, this presents in a pathogenically similar way to heparin-induced thrombocytopenia (HIT), which is a common prothrombotic complication of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) therapies. In a vaccinated patient, the symptoms have been seen to develop from five to 30 days after the first vaccine dose, further reflecting an immunological pattern like that of HIT.

            If the patient is not receiving heparin therapy, a warning sign would be a low platelet count, with low fibrinogen and disproportionally raised D-dimer. For vaccinated patients presenting with these symptoms, additional specialist investigation running an enzyme-linked immunosorbent assay (ELISA) such as Stago’s Asserachrom HPIA becomes necessary.3

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024